2017_SBRT_Course Book

Retrospective Analysis Weickhardt JTO 2012 • 65 metastatic NSCLC patients • ALK+ and EGFR-MT treated with Crizotinib and Erlotinib, respectivey Oligo-progression: SBRT & systemic Tx beyond progression

25 / 51 of progressive patients: SBRT

65 patients Crizotinib Erlotinib

6/25 Remained FFP

PFS 9-14 mo

PFS 6 mo

Ø Oligo-progression in 20 – 50% Ø Phase II EORTC HALT study in preparation

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

13

/

HALT study in preparation

Advanced NSCLC EGFR / ALK + with response to TKI

TKI

Progression

Widespread Progression

Oligo- Progression

Randomise (2:1)

SABR & continue TKI

Continue TKI

Ø Oligo defined as max. 3 metastases Ø SBRT doses below 100Gy BED

/ 07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

14